mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way

Core Insights - The mRNA cancer vaccines and therapeutics market is projected to grow from $52.85 billion in 2023 to $61.52 billion in 2024, with a compound annual growth rate (CAGR) of 16.4% [2][11] - By 2028, the market size is expected to reach $113.41 billion, reflecting a CAGR of 16.5% [2][11] Market Growth Drivers - Growth in the mRNA cancer vaccines and therapeutics market is driven by factors such as changing lifestyles, increased funding in medical research, favorable regulatory environments, established healthcare infrastructures, and ongoing development of new therapeutic pipelines [3] - Promising clinical trial results, rising awareness of mRNA technology, significant unmet medical needs, and the potential for improved patient outcomes are expected to further fuel market growth [4][5] Market Trends - Anticipated trends include expansion into new therapeutic areas, personalized medicine approaches, advancements in mRNA delivery systems, development of multivalent mRNA vaccines, and integration of artificial intelligence in mRNA design [4] - The increasing prevalence of cancer, influenced by sedentary lifestyles and environmental factors, is expected to drive demand for mRNA cancer vaccines and therapeutics [5] Competitive Landscape - Leading companies in the mRNA cancer vaccines and therapeutics market include Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis SA, and Moderna Therapeutics Inc., among others [6][8] - Companies are focusing on innovative treatments, particularly mRNA cancer vaccines, to meet the rising demand for effective cancer therapies [6] Regional Insights - North America was the largest market for mRNA cancer vaccines and therapeutics in 2023, while Asia Pacific is anticipated to be the fastest-growing region in the forecast period [9]